TPH1 Inhibitors for Peripheral Serotonin Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drugs that affect serotonin levels, such as MAO inhibitors and SSRIs, often cause severe adverse effects due to their impact on blood serotonin levels, and there is a lack of safe and effective inhibitors for tryptophan hydroxylase (TPH), which is crucial for serotonin synthesis.
Innovation Solution
Development of compositions comprising a TPH inhibitor and another drug that can cause serotonin-mediated adverse effects, specifically using compounds that inhibit TPH1 to reduce these adverse effects by targeting peripheral serotonin levels without affecting central nervous system serotonin levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If drugs that affect serotonin levels (MAO inhibitors, SSRIs) are administered to treat mood disorders, then therapeutic effects are achieved, but severe adverse effects occur due to impact on blood serotonin levels
Solution Approach 1:
The invention segments the serotonin synthesis pathway by selectively inhibiting TPH1 in peripheral tissues while leaving TPH2 in the central nervous system unaffected. This spatial segmentation allows differential control of serotonin levels in different body compartments, achieving therapeutic benefits while avoiding adverse effects from peripheral serotonin accumulation
Solution Approach 2:
The patent applies local quality by designing TPH1 inhibitors that specifically target peripheral serotonin synthesis without affecting central serotonin production. This localized inhibition allows the drug to have different effects in different locations: reducing peripheral serotonin to prevent adverse effects while maintaining central serotonin for continued therapeutic action
2Productivity
If fenfluramine and phentermine are combined for weight loss, then appetite suppression is achieved, but cardiotoxicity occurs due to disruption of blood serotonin level control
Solution Approach 1:
The invention applies preliminary anti-action by pre-treating with or co-administering a TPH1 inhibitor to block the harmful cardiotoxic effects before they can occur. The TPH1 inhibitor prevents peripheral serotonin accumulation that would otherwise be caused by fenfluramine-phentermine combination, thereby preemptively counteracting the cardiotoxic mechanism while allowing the weight loss therapy to proceed
3Object-affected harmful factors
If TPH inhibitors are developed to reduce peripheral serotonin levels, then adverse effects are minimized, but selective inhibition of TPH1 without affecting TPH2 must be achieved
Solution Approach 1:
The patent achieves selectivity through local quality by designing molecular structures that specifically bind to TPH1's active site while excluding TPH2. The chemical compounds contain structural features that match TPH1's binding pocket geometry and chemical environment, creating high affinity for TPH1 but low affinity for TPH2, thus achieving selective peripheral inhibition without central effects
Solution Approach 2:
The invention utilizes parameter changes by modifying chemical structure parameters of the inhibitor molecules to optimize TPH1 selectivity. By adjusting molecular size, shape, functional groups, and electronic properties, the compounds achieve optimal binding to TPH1 while maintaining selectivity against TPH2, thereby resolving the selectivity challenge through systematic parameter optimization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The TPH inhibitors effectively reduce serotonin-mediated adverse effects, such as cardiovascular and gastrointestinal issues, while maintaining normal serotonin levels in the central nervous system, thereby improving the safety and efficacy of serotonin-related drug treatments.
Implementation Method 1
The first step is rate-limiting, and is catalyzed by the enzyme tryptophan hydroxylase (TPH)
Implementation Method 2
The principle route by which serotonin is removed from the body involves the enzyme monoamine oxidase (MAO), which converts the compound to 5-hydroxyindole acetaldehyde, which is then converted to 5-hydroxyindole acetic acid (5-HIAA) by the enzyme aldehyde dehydrogenase
Data Source
AI summary
Methods and compositions comprising tryptophan hydroxylase inhibitors are disclosed. Particular methods are directed at reducing or avoiding serotonin-mediated adverse effects associated with some drugs.